TP53 and cancer: Upon p53 activation by doxorubicin treatment in several cancer cell lines, PFT-α efficiently inhibited both Ser33 and Ser15 phosphorylation, but not Ser37 (Fig. 2C,D and Supplementary Fig. S2D).